
    
      A 48 Week, Phase II, Open-label, Multi-Cohort, Multicenter Study to Evaluate the Safety,
      Tolerability, Pharmacokinetics and Antiviral Activity of GW433908/Ritonavir QD and
      GW433908/Ritonavir BID when Administered to HIV-1 Infected, Antiretroviral Naive and
      Experience Pediatric Subjects 2 to 18 Years Old

      ViiV Healthcare is the new sponsor of this study, and GlaxoSmithKline is in the process of
      updating systems to reflect the change in sponsorship
    
  